Enhanced Enterovirus D68 Replication in Neuroblastoma Cells Is Associated with a Cell Culture-Adaptive Amino Acid Substitution in VP1

Syriam Sooksawasdi Na Ayudhya,a Adam Meijer,b Lisa Bauer,a Bas Oude Munnink,a Carmen Embregts,a Lonneke Leijten,a Jouke Y. Siegers,a Brigitta M. Laksono,a Frank van Kuppeveld,c Thijs Kuiken,a Corine GeurtsvanKessel,a and Debby van Riela

aDepartment of Viroscience, Erasmus MC, Rotterdam, The Netherlands
bNational Institute for Public Health and the Environment, Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, Bilthoven, The Netherlands
cVirology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

ABSTRACT Since its emergence in the United States in 2014, enterovirus D68 (EV-D68) has been and is associated with severe respiratory diseases and acute flaccid myelitis. Even though EV-D68 has been shown to replicate in different neuronal cells in vitro, it is currently poorly understood which viral factors contribute to the ability to replicate efficiently in cells of the central nervous system and whether this feature is a clade-specific feature. Here, we determined the replication kinetics of clinical EV-D68 isolates from (sub)clades A, B1, B2, B3, and D1 in human neuroblastoma cells (SK-N-SH). Subsequently, we compared sequences to identify viral factors associated with increased viral replication. All clinical isolates replicated in SK-N-SH cells, although there was a large difference in efficiency. Efficient replication of clinical isolates was associated with an amino acid substitution at position 271 of VP1 (E271K), which was acquired during virus propagation in vitro. Recognition of heparan sulfate in addition to sialic acids was associated with increased attachment, infection, and replication. Removal of heparan sulfate resulted in a decrease in attachment, internalization, and replication of viruses with E271K. Taken together, our study suggests that the replication kinetics of EV-D68 isolates in SK-N-SH cells is not a clade-specific feature. However, recognition of heparan sulfate as an additional receptor had a large effect on phenotypic characteristics in vitro. These observations emphasize the need to compare sequences from virus stocks with clinical isolates in order to retrieve phenotypic characteristics from original virus isolates.

IMPORTANCE Enterovirus D68 (EV-D68) causes mild to severe respiratory disease and is associated with acute flaccid myelitis since 2014. Currently, the understanding of the ability of EV-D68 to replicate in the central nervous system (CNS), and whether it is associated with a specific clade of EV-D68 viruses or specific viral factors, is lacking. Comparing different EV-D68 clades did not reveal clade-specific phenotypic characteristics. However, we did show that viruses which acquired a cell culture-adapted amino acid substitution in VP1 (E271K) recognized heparan sulfate as an additional receptor. Recognition of heparan sulfate resulted in an increase in attachment, infection, and replication in neuroblastoma cells compared with viruses without this specific amino acid substitution. The ability of EV-D68 viruses to acquire cell culture-adaptive substitutions which have a large effect in experimental settings emphasizes the need to sequence virus stocks.

KEYWORDS VP1, cell culture adaptation, enterovirus D68, heparan sulfate, in vitro, neuroblastoma cells, neurotropism, pathogenesis, replication

Enterovirus D68 (EV-D68) is known to cause mild to severe respiratory infections, but since 2014 it has been increasingly associated with neurological complications (1–3). After its discovery in 1962, cases were only sporadically reported (4). EV-D68
caused a large outbreak of severe respiratory disease across the United States of which about 10.4% of symptomatic cases developed acute flaccid myelitis (AFM) from August 2014 to January 2015 (5). During this outbreak, more than 2,000 cases of EV-D68 infections were reported in 20 countries (6–9), of which about 7% of symptomatic cases developed AFM (10). Other neurological complications like cranial nerve dysfunction and encephalitis were occasionally reported (11–13). Since then, biennial epidemics of EV-D68 occur globally, with the largest epidemic in 2018 (14–17).

EV-D68 belongs to the Enterovirus genus in the Picornaviridae family. It is a nonenveloped, positive-sense, single-stranded RNA virus. Within the capsid, the structural protein VP1 plays an important role in the attachment to host cells, and its gene is the most variable part of the genome and used for genotyping (18). Circulating EV-D68 isolates use cell surface glycoproteins including sialylated glycoproteins or glycolipid as a receptor. These sialylated receptors bind to the canyon in VP1, which leads to conformational change and subsequent dysregulation of stability and thereby initiates uncoating (19). However, recent studies have identified nonsialylated receptors, such as ICAM-5 and heparan sulfate glycosaminoglycans (GAGs), for specific EV-D68 isolates (20, 21).

To date, EV-D68 is divided into four clades, from A to D, although the initial division in three clades, A, B, and C, with subclades A1 and A2, is also used. Some researchers use A for A1 and D for A2 (22, 23). EV-D68 clade B is subdivided into subclades B1, B2, and B3 (24), and clade D has recently been subdivided into subclades D1 and D2 (25). Multiple clades circulated during the 2014 outbreak, but subclade B1 was the most prevalent and was also associated with neurological complications. Based on this observation, it was initially thought that the ability to invade and replicate in the central nervous system (CNS) was a recently acquired feature and clade specific (2, 3, 8, 10, 26). However, since 2016, subclade B3 and to a lesser extent subclade D1 became predominant, and both were associated with neurological complications (16, 27–29). In addition, recent studies have shown that multiple isolates from different clades are able to infect both neuronal cells and neuroblastoma cell lines (30) and that non-subclade B1 and B3 isolates were able to cause paralysis in mice after intracranial inoculation. Interestingly, isolates from the same clade differed in their ability to cause paralysis in mice (31). Altogether, this suggests that the ability to invade and replicate in the CNS is not a clade-specific feature. Even though several studies have determined the in vitro phenotypic characteristics of EV-D68 isolates in cells of the CNS, viral factors associated with efficient attachment, infection, and replication have not been identified yet. In addition, genetic analysis of EV-D68 isolates associated with phenotypic characteristics in vitro has not been carried out in previous studies.

In this study, we investigated the ability of EV-D68 isolates from different clades to attach and infect human neuroblastoma cells (SK-N-SH) and determined their replication kinetics. Subsequently, we compared viral sequences in order to identify viral factors associated with increased viral replication.

RESULTS

Clinical enterovirus D68 isolates from different clades replicate in human neuroblastoma cells with different efficiency. Growth curves using a multiplicity of infection (MOI) of 0.01 were generated for clinical isolates of clade A (or A1; here we use A), subclade B1, subclade B2 (B2/039 and B2/947), subclade B3, subclade D1 (or A2; here we use D1), and the prototype Fermon strain in SK-N-SH and rhabdomyosarcoma (RD) cells. Growth curves showed that all viruses replicated in SK-N-SH cells, but virus titers of subclades B2/947 and B3 and Fermon were significantly higher than those of clade A and subclades D1, B1, and B2/039 from 24 h postinoculation (hpi) onward (Fig. 1A). Remarkable, large differences between the two subclade B2 isolates were observed in growth kinetics on SK-N-SH cells. The same pattern was observed in RD cells, but the differences among isolates were smaller. Isolates that replicated most efficiently on SK-N-SH cells also did so in RD cells (Fig. 1B). Overall, these data show that EV-D68...
isolates from all clades are able to replicate in SK-N-SH and RD cells but do so with different efficiency.

**Replication efficiency is associated with percentage of infection.** To study whether the replication efficiency was associated with the infection efficiency of the different EV-D68 isolates, the percentage of infection was determined by immunofluorescence using an anti-VP1 antibody after incubation of viruses on SK-N-SH and RD cells with an MOI of 2 for 8 h. Viruses of clade B2/947 and Fermon, and to a lesser extent B3, which replicated most efficiently in SK-N-SH and RD cells, infected higher percentages of cells than did other isolates (Fig. 2A and B). These results suggest that the efficient replication measured by the growth kinetics was associated with efficient infection of cells.

**Amino acid differences between viruses of subclade B.** Since we observed a large difference in the replication kinetics between the two isolates of subclade B2, we initially performed full genome sequencing analysis of the stocks from B2/039 and B2/947 isolates. There were 13 amino acid differences between these two viruses: V66A, R67K, K116R, V166I, R234G, V136M, D140N, E271K, R25K, I37V, K56R, I187V, and S56R (Table 1). These amino acid differences were present in both structural proteins (VP4, VP2, VP3, and VP1) and nonstructural proteins (2A, 3C, and 3D).
A lysine is present at position 271 of capsid protein VP1 in clinical isolates that replicate efficiently in SK-N-SH and RD cells. After the identification of amino acid differences between the two clinical isolates of subclade B2, the 13 amino acid positions that differed were verified in the other clinical isolates to identify amino acid substitutions possibly associated with increased infection and replication efficiency. A lysine (K) at position 271 in the VP1 capsid protein was observed only in clade B2/947 and B3 viruses, the two clinical isolates that replicated most efficiently in SK-N-SH and RD cells. All other clinical isolates had a glutamic acid (E) or valine (V) at position 271 in VP1, and the lab-adapted Fermon carried an aspartic acid (D) (Table 2). At all other positions that differed between the clade B2 isolates, no common differences were observed between the viruses with different replication efficiencies (Table 2). This indicates that the amino acid substitution E271K might be a determinant for increased infection and replication in SK-N-SH cells in vitro.

A lysine at position 271 in VP1 is acquired during in vitro passaging. The clinical isolates used in this study were passaged in RD cells to produce virus stocks. To investigate whether a lysine at position 271 in VP1 was present in the original isolate of the patient, sequences from clinical specimens, previous passages, and virus stocks used in this study were generated and aligned. In the clinical specimens, a glutamic acid (E) was found at position 271 in VP1 of both subclade B2/947 (21) and subclade B3. Furthermore, sequencing analysis of all virus passages showed the acquisition of a lysine (K) in passage 3 of subclade B2/947 and passage 2 of subclade B3 on RD cells (Table 3). There were no minor variants present at position 271 of sequences derived from clinical specimens and stock B2/947 and B3 viruses using a 20% cutoff (Table 3). This indicates that viruses with high replication and infection efficiency acquired the E271K amino acid substitution during passaging in RD cells.

Viruses with the E271K substitution in VP1 attached more efficiently to SK-N-SH and RD cells. Since the amino acid at position 271 of EV-D68 resides within the canyon, close to the sialic acid binding site (19), we investigated whether EV-D68 isolates with the specific E271K amino acid substitution attached to higher percentages of SK-N-SH and RD cells. We observed that the subclade B2/947 and subclade B3 isolates which acquired the E271K substitution attached to higher percentages of SK-N-SH and RD cells than did all other isolates. Fermon attached to lower percentages of SK-N-SH and RD cells despite efficient replication and infection (Fig. 3A and B).

**TABLE 1** Amino acid differences between clade B2/947 and clade B2/039 isolates

| Amino acid at position in protein |
|----------------------------------|
|                            | VP4 | VP2 | VP3 | VP1 | 2A | 3C | 3D |
|----------------------------------|-----|-----|-----|-----|----|----|----|
| Isolate                          | 66  | 67  | 116 | 166 | 234| 136| 140| 271 | 25 | 37 | 56  | 187 | 56 |
| B2/947                           | A   | K   | R   | I   | G  | M  | N  | K   | K   | V  | R   | V   | R  |
| B2/039                           | V   | R   | K   | V   | R  | V  | D  | E   | R   | I  | K   | I   | S  |

**TABLE 2** Amino acids present in clinical isolates of (sub)clades A, B1, B2, B3, and D1 and Fermon at the positions that differed between low- and high-replicating isolates

| Amino acid at position in protein |
|----------------------------------|
|                            | VP4 | VP2 | VP3 | VP1 | 2A | 3C | 3D |
|----------------------------------|-----|-----|-----|-----|----|----|----|
| Isolate                          | 66  | 67  | 116 | 166 | 234| 136| 140| 271 | 25 | 37 | 56  | 187 | 56 |
| B2/947                            | A   | K   | R   | I   | G  | M  | N  | K   | K   | V  | R   | V   | R  |
| B3                               | A   | R   | K   | I   | G  | V  | D  | K   | R   | I  | R   | V   | S  |
| B2/039                            | V   | R   | K   | V   | R  | V  | D  | E   | R   | I  | K   | I   | S  |
| B1                               | A   | K   | K   | V   | A  | M  | D  | E   | R   | I  | K   | V   | S  |
| D1                               | A   | K   | K   | I   | G  | V  | D  | V   | R   | V  | R   | V   | S  |
| Fermon                            | A   | R   | K   | I   | G  | M  | D  | D   | R   | V  | R   | V   | S  |

*Isolates that replicate efficiently in SK-N-SH cells.*

Sooksawasdi Na Ayudhya et al.

November/December 2020 Volume 5 Issue 6 e00941-20

msphere.asm.org 4
Overall, these observations suggest that the E271K substitution is associated with increased virus attachment in vitro.

**Viruses with E271K substitution in VP1 recognize sialic acid and heparan sulfate.** A previous study has shown that among several EV-D68 strains, subclade B2/947 can recognize heparan sulfate as an additional receptor to sialic acid (21). To investigate whether our viruses with an E271K substitution were able to recognize both sialic acid and heparan sulfate, we determined the ability of these viruses to attach to cells that were pretreated with *Arthrobacter ureafaciens* neuraminidase and heparinase III to remove sialic acids or heparan sulfate, respectively. Subclade B2/947 and B3 isolates carrying the E271K substitution, and the subclade B2/039 isolate (271E) as control, were included in these analyses. Removal of sialic acids and heparan sulfate was confirmed by measuring mean fluorescent intensity (MFI) with *Maackia amurensis* lectin (MAL) for α(2,3)-linked sialic acid and *Sambucus nigra* lectin (SNA) α(2,6)-linked sialic acid, and with an antibody that recognizes heparan sulfate (Fig. 4A and D). The percentage of cells to which the virus attached was significantly decreased for all viruses in both SK-N-SH and RD cells after neuraminidase treatment (Fig. 4B and C). In contrast, heparinase III treatment resulted in decreased attachment of only viruses with the E271K substitution (Fig. 4E and F). Overall, these results showed that the viruses with the E271K substitution recognize both sialic acid and heparan sulfate on the cellular surface.

**Attachment, internalization, and replication of viruses with E271K substitution in VP1 depend in part on heparan sulfate recognition.** To investigate if heparan sulfate is required for attachment, internalization, and replication of viruses with an E271K substitution, heparan sulfate was removed on SK-N-SH and RD cells by either

### TABLE 3 Amino acid at position 271 of VP1 in isolates B2/947 and B3 from original clinical specimens and historical passages

| Isolate | Clinical specimen/ virus isolate passage | Amino acid at position 271 | Frequent variant; method | GenBank accession no. |
|---------|------------------------------------------|---------------------------|--------------------------|-----------------------|
| B2/947  | Clinical specimen                         | E                         | 100%; Illumina           | KT231897              |
|         | Passage 1                                 | Position not sequenced     |                          |                       |
|         | Passage 2                                 | E                         | 100%; Sanger             | KT231898              |
|         | Passage 3                                 | K                         | 100%; Sanger             |                       |
|         | Passage 4                                 | K                         | 100%; Illumina           | MN954540              |
| B3      | Clinical specimen                         | E                         | 100%; Sanger             |                       |
|         | Passage 1                                 | E                         | 100%; Sanger             |                       |
|         | Passage 2                                 | K                         | 100%; Illumina           |                       |
|         | Passage 3                                 | K                         | 100%; Illumina           |                       |
|         | Passage 4                                 | K                         | 100%; Illumina           |                       |

**FIG 3** Virus attachment of EV-D68 viruses to SK-N-SH and RD cells. Experiments were performed using flow cytometry. Attachment of clinical isolates from (sub)clades A, B1, B2, B3, and D1 and prototype strain Fermon to SK-N-SH cells (A) and RD cells (B). Heat-inactivated viruses were included as negative control. Statistical analysis was performed using the one-way ANOVA in comparison to Fermon. Data are shown as mean ± SD from three independent experiments. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
heparinase III or NaClO₃, which prevents cell surface sulfation (21). Treated and untreated cells were inoculated with an MOI of 1 of B2/947, B3, and B2/039. After 1 hpi at 37°C, the amount of attached and internalized viral RNA of B2/947 and B3 was smaller in the heparinase III- or NaClO₃-treated cells than in untreated cells by qPCR. Viral RNA for B2/039 was not reduced in the heparinase- or NaClO₃-treated cells, with the exception of a minimal but significant reduction of viral RNA in SK-N-SH cells treated with NaClO₃ but not in RD cells (Fig. 5A and B). Virus replication of both B2/947 and B3 was significantly decreased in SK-N-SH and RD cells treated with heparinase III or NaClO₃, while replication levels of B2/039 were similar in treated and untreated cells (Fig. 5C and D; see also Fig. S1 in the supplemental material). Together, these results indicate that the recognition of heparan sulfate is important for facilitating virus attachment, internalization, and replication.

**DISCUSSION**

Here, we report that EV-D68 isolates from (sub)clades A, B1, B2, B3, and D1 replicated in human neuroblastoma SK-N-SH cells; however, large differences were observed in replication efficiency. Subsequent genotypic analysis revealed that viruses replicating most efficiently had a specific amino acid substitution in VP1 (E271K). This substitution was acquired during cell culture propagation and was associated with the recognition of heparan sulfate. Furthermore, attachment, internalization, and replication depended in part on heparan sulfate recognition for viruses with the E271K substitution in VP1. These findings suggest that efficient replication of EV-D68 isolates in vitro in human neuroblastoma cells is not a clade-specific feature but at least in part associated with the usage of heparan sulfate as an additional receptor.

The amino acid substitution at position 271 of VP1 (E271K) acquired during in vitro passaging in 2 out of the 6 viruses included in our study was associated with the recognition of heparan sulfate as an additional receptor (21), which had a large impact on the phenotypic characteristics of EV-D68 viruses. Heparan sulfate is abundantly

![FIG 4](image-url) Virus attachment of clinical isolates B2/039, B2/947, and B3 after neuraminidase and heparinase III treatment. (A) Mean fluorescent intensity (MFI) levels of MAL (α(2,3)-linked sialic acid) and SNA (α(2,6)-linked sialic acid) with and without neuraminidase treatment. (B and C) Percentage of attachment of isolates B2/039, B2/947, and B3 with and without neuraminidase treatment of SK-N-SH cells (B) and RD cells (C). (D) MFI levels of heparan sulfate with and without heparinase III treatment. (E and F) Attachment of clinical isolates B2/039, B2/947, and B3 with and without heparinase III treatment on SK-N-SH cells (E) and RD cells (F). Statistical analysis was performed by paired t test. Data are shown as mean ± SD from three independent experiments. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
expressed on RD cells (32) and associated with increased virus attachment, infection efficiency, and virus replication in cells in vitro. The ability of EV-D68 to replicate in mouse neuroblastoma cells and human induced pluripotent stem cell motor neurons were independent of sialic acid recognition, although the usage of heparan sulfate was not investigated (30, 33). In our study, unfortunately, viruses from earlier passages without E271K in VP1 were not available and an infectious clone of the clinical isolate B2/947 with the original VP1 amino acid E271 could not be recovered (21), which made a direct comparison of viruses with and without E271K in VP1 not possible. The lysine at position 271 of VP1 is positively charged, which contributes to the formation of a basic patch that interacts with negatively charged heparan sulfate proteoglycan (21). This mechanism has been described previously for other picornaviruses which acquired the recognition of heparan sulfate during passaging of viruses in vitro (34–36).

It was initially thought that the neurotropic potential of EV-D68 was a feature recently acquired and was associated with subclade B1. However, epidemiological and clinical data have shown that different subclades, namely, B3 and D1, besides subclade B1 have also been associated with AFM cases after 2014 (16, 28, 29). In addition, most in vitro studies, including ours, and in vivo studies do not reveal phenotypic difference between clades or recent and older EV-D68 isolates (30, 31, 37). In vivo, EV-D68 isolates from multiple clades (e.g., clade A and subclade B1) were able to cause paralysis after intracranial inoculation (31). In vitro, we and others showed that EV-D68 isolates from multiple clades were able to replicate in neuroblastoma cells (37). Furthermore, we did not detect phenotypic differences between viruses isolated before and after 2014 independent of the clade, which correlates with the study by Rosenfeld et al. (30), but not with a study performed by Brown et al. (37). Unfortunately, virus stocks were not compared with clinical isolates in these studies. All together, these data suggest that the ability to replicate in cells of the CNS is not a clade-specific feature.
The role of heparan sulfate as an additional receptor in the pathogenesis in vivo remains unclear. Although the presence of the E271K substitution in human EV-D68 isolates has not been studied, we found that only a very few EV-D68 VP1 sequences available in GenBank have a lysine at position 271 of VP1 (by 15 December 2019, 17 out of 1,737 [<1%]), and they fall in a wide range of old and current clades. However, of most sequences the source, clinical material or virus isolate, and passage history are not known. Interestingly, acquisition of heparan sulfate recognition in an immunocompromised patient with enterovirus 71 (EV-71) was associated with systemic spread, including the CNS. In this patient a mutation in the VP1 responsible for heparan sulfate recognition was detected only in extrarespiratory samples (38). Since heparan sulfate is not expressed on the apical side of respiratory epithelial cells, but abundantly in cells outside the respiratory tract, such as cells of the CNS and muscle cells (38, 39), in vivo acquisition of E271K might—just like EV-71—occur outside the respiratory tract and would therefore hardly be found in respiratory samples. Sequence analysis of respiratory and extrarespiratory samples from the same patient should reveal if heparan sulfate recognition is important for the pathogenesis of EV-D68 in vivo.

It remains unclear why there has been an increase of AFM cases associated with EV-D68 since 2014, since epidemiological and serological studies suggest that EV-D68 has been circulating throughout the population for decades (40, 41). Currently, the pathogenesis of neurological disease associated with EV-D68 infection is not fully understood. Either a direct effect of virus entry and replication in the nervous system or an indirect effect of systemic cytokines could contribute. However, the detection of EV-D68 or virus-specific antibodies in the cerebrospinal fluid suggests that virus enters and replicates in the CNS in at least some of the patients (42, 43). As there have been more cases with severe respiratory disease caused by EV-D68 since 2014 (9, 44), it might be that recent EV-D68 viruses replicate to higher titers in the respiratory tract, thereby increasing the risk of systemic spread including that to the CNS. However, understanding the exact mechanism of systemic spread of EV-D68 in vivo requires more in-depth pathogenesis studies.

Taken together, we demonstrate that the replication of EV-D68 isolates in the neuroblastoma cell line SK-N-SH is not a clade-specific phenotype of EV-D68. However, large phenotypic differences that we did observe in vitro could be linked to the substitution E271K in VP1 leading to the recognition of heparan sulfate as an additional receptor, which resulted in increased attachment, internalization, and replication. Therefore, we recommend sequencing of virus stocks in order to obtain viruses that resemble clinical isolates in order to study phenotypic characteristics of EV-D68 isolates in vitro and in vivo.

**MATERIALS AND METHODS**

**Cells.** Rhadomyosarcoma (RD cells) (ATCC) were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Basel, Switzerland) supplemented with 10% (vol/vol) fetal calf serum (FCS; Sigma-Aldrich, St. Louis, MO, USA), 100 IU/ml penicillin (Lonza), 100 IU/ml streptomycin (Lonza), and 2 mM L-glutamine (Lonza); at 37°C with 5% CO2. SK-N-SH neuroblastoma cells (Sigma-Aldrich) were maintained in Eagle’s minimum essential medium (EMEM) and Earle’s balanced salt solution (EBSS) (Lonza), 10% (vol/vol) FCS, 100 IU/ml penicillin (Lonza), 100 μg/mL streptomycin (Lonza), 2 mM L-glutamine (Lonza), 1% nonessential amino acids (Lonza), 1 mM sodium pyruvate (Thermo Fisher Scientific, Waltham, MA, USA), and 1.5 mg/ml sodium bicarbonate (Lonza), at 37°C with 5% CO2. All SK-N-SH cells used in the study were from the same batch and maintained up to 15 passages.

**Viruses.** Enterovirus D68 viruses included in this study were isolated from clinical specimens at the National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands. The viruses were initially isolated on RD cells at 33°C at RIVM from patients with respiratory disease caused by EV-D68 infection. Virus stocks for the in vitro studies were grown at the Viroscience laboratory, Erasmus MC (EMC), Rotterdam, The Netherlands, in RD cells (ATCC) at 33°C in 5% CO2. The viruses included in this study, with virus reference number, year of collection and isolation, passage number, and accession number are as follows: clade A (or A1) (4311200082; 2012, passage RD3, accession number MN954536) (45)), D subclade D1 (or A2) (4311400720; 2014, passage RD4, accession number MN954537) (45); B1 (4311300117; 2013, passage RD4, accession number MN954538) (45), B2 (4311201039; 2012, passage RD3, accession number MN954539) (45), B2/947 (4310900947; 2009, passage RD4, accession number MN954540) (19, 46), and B3 (4311601013; 2016, passage RD4, accession number MN954541). EV-D68 prototype Fermon was provided by Frank van Kupperveld, Utrecht University, Utrecht, The Netherlands.
**Virus titrations.** Virus titers (median tissue culture infectious dose [TCID₅₀]) of the virus stocks were determined by endpoint titrations in RD cells. Briefly, 10-fold serial dilutions were made and inoculated onto a monolayer of RD cells. The inoculated plates were incubated at 33°C in 5% CO₂. Cytotoxic effect (CPE) was determined at day 5, and virus titers were determined using the Spearman-Kärber method (47).

**Replication kinetics, virus infection, and internalization.** Virus infection by EV-D68 isolates was determined using a multiplicity of infection (MOI) of 0.01 or 1. Monolayers of SK-N-SH and RD cells in a 6-well plate or a 96-well plate were inoculated with the different EV-D68 viruses at 1 h at 37°C in 5% CO₂ or cell culture medium as a control. After 1 h of virus adsorption, the inoculum was removed, and cells were washed once with PBS before the cells were lysed with lysis buffer (Roche, The Netherlands) for qPCR analysis or replenished with culture medium and incubated at 37°C in 5% CO₂. The supernatant was collected at the indicated hour postinoculation (hpi) and stored at −80°C for subsequent virus titration.

**Percentage of infections.** SK-N-SH and RD cells (~80% confluent) in a 96-well plate were infected with EV-D68 at an MOI of 2. Mock-infected cells were included as a negative control. EV-D68-infected SK-N-SH and RD cells were incubated at 37°C and 33°C in 5% CO₂, respectively. After 8 hpi, cells were fixed with 4% paraformaldehyde (PFA) for 20 min at room temperature, washed with PBS, and permeabilized with 70% ethanol. Cells were first incubated with 5% bovine serum albumin (BSA; Aurion, Wageningen, The Netherlands) in PBS for 30 min before incubation with rabbit anti-EV-D68 VP1 (20 μg/ml; GeneTex, Irvine, CA, USA) for 1 h. Cells were washed twice with PBS and incubated with goat anti-rabbit IgG conjugated with Alexa Fluor 594 (10 μg/ml; Life Technologies, Inc., The Netherlands) in PBS with 0.1% BSA (Aurion) for 1 h. Cells were washed 3 times with PBS and mounted with ProLong Diamond Antifade with DAPI (4',6-diamidino-2-phenylindole; Life Technologies) to visualize nuclei. Each experiment included negative and omission controls. EV-D68 VP1-positive cells were identified using a Zeiss LSM 700 laser scanning microscope. All images were processed using Zen 2010 software. Per sample, 3 high-power fields were photographed, and the number of infected cells was calculated by counting virus-infected/uninfected cells in 3 randomly chosen panels. All experiments were performed in triplicate.

**Next-generation sequencing.** After pretreatment of the virus stock with OmniCleave (Lucigen, Halle-Zoersel, Belgium), RNA was extracted using the NucleoSpin RNA II kit (Bioké, Leiden, The Netherlands) according to the manufacturer’s instructions. First-strand cDNA was synthesized using random hexamers and Superscript IV (Thermo Fisher Scientific). Double-stranded DNA was generated using Klenow fragment (New England Biolabs [NEB]). For library preparation, the Kapa HyperPlus library preparation kit (Roche, Basel, Switzerland) was used according to the manufacturer’s instructions with minor modifications. Adapters were diluted 1:10, and a second wash step was performed after adapter ligation. The sequenced reads were mapped using an Illumina MiSeq to generate 2 × 300-bp sequence reads.

**Data analysis for Illumina sequencing.** Raw sequence reads were quality controlled using fastp (48). The quality-controlled reads were normalized using bbnorm (49) and subsequently de novo assembled using SPAdes (50). Minimap2 (51) was used to align the quality-controlled reads against the obtained contigs and the obtained bam files were loaded into Geneious (52) for minor variant determination with a 20% cutoff.

**Sequencing alignment.** Each segment of viral genome was aligned using the CLUSTAL W algorithm in MEGAS5 (53). Next, sequences of all individual isolated were aligned using the BioEdit version 7.0. The 5’ untranslated region or noncoding region was resected from sequences.

**Virus attachment.** Cell suspensions of SK-N-SH or RD cells were incubated with EV-D68 strains for 1 h at 4°C using an MOI of 1. As a negative control, viruses were heat inactivated at 62°C for 10 min before inoculation of the cells. Subsequently, cells were washed with PBS, fixed with 4% PFA for 15 min, and blocked for 30 min with PBS containing 5% normal goat serum (Dako, Denmark). Cells were incubated with rabbit anti-EV-D68 VP1 (20 μg/ml; GeneTex) in 2 mM EDTA (Sigma-Aldrich) and 0.1% BSA (Aurion) fluorescence-activated cell sorting (FACS) buffer for 1 h at 4°C. After washing 3 times, cells were incubated with a secondary goat-anti-rabbit IgG conjugated to Alexa Fluor 594 (10 μg/ml; Life Technologies) in FACS buffer. After incubation, cells were washed 3 times in FACS buffer and analyzed using a BD FACS Lyics flow cytometer (BD Bioscience, USA). The percentage of cells to which virus attached was determined using FlowJo 10 software (Ashland, OR, USA). Experiments were performed at least 3 times, and each experiment was performed in duplicate.

**Removal of cell surface sialic acid and heparan sulfate.** Cell suspensions of SK-N-SH or RD cells were incubated with 100 mIU/ml Arthrobacter ureafaciens neuraminidase (Roche) or 10 mIU/ml heparinase III (Sigma-Aldrich) in serum-free medium for 1 h at 37°C. To prevent the cell surface sulfation, cells were cultured for 5 days with 80 mM sodium chlorate (NaClO₃; Sigma-Aldrich, 1.06420 EMD Millipore). Removal of α(2,3)-linked sialic acid and α(2,6)-linked sialic acid on the cell surface was confirmed by staining with fluorescein-labeled Sambucus nigra lectin (SNA) (5 μg/ml; Vector Laboratories, CA, USA) and biotinylated Maackia amurensis lectin (MAL) I (5 μg/ml; Vector Laboratories). The sialylated cells were detected by streptavidin-conjugated Alexa Fluor 488 (5 μg/ml; Thermo Fisher Scientific). Removal of heparan sulfate on the cell surface was confirmed using a mouse anti-heparan sulfate monoclonal antibody (10 μg/ml; Amsbio, Frankfurt, Germany). No-virus inoculation control and virus inoculation in nonenzymatic treatment control were included as a negative control and positive control, respectively, in all assays. Mean fluorescence intensity (MFI) was measured with BD FACS Lyics (BD Bioscience). Subsequently, virus attachment was determined as described above. Data were analyzed using FlowJo 10 software (Ashland, OR, USA). The experiments were performed at least 3 times, and each experiment was performed in duplicate.

**RT-qPCR.** Total nucleic acid was extracted from cell lysis using the Magna Pure MagNA Pure LC total nucleic acid isolation kit (Roche) according to manufacturer’s instructions. The total nucleic acid was
eluted in 50 μL. For viral RNA quantification, a real-time TaqMan RT-PCR assay was performed using the Applied Biosystems 7500 real-time PCR system (Thermo Fisher Scientific). TP-PCR experiments were carried out by adding forward and reverse EV-D68 primer (75 pmol/μL) and the probes (10 pmol/μL). The following sequences including EV-D68 specific primer and probe were used: forward primer 5'-TGTCC CACGTTGAAAAACAA-3', reverse primer 5'-TGTTAGCTGCTCATGGTTTTCAC-3', probe 1 5'-TCCGCTTATAG TACTTG-3', and probe 2 5'-ACCCTATAGTACTTG-3'. The following reaction conditions were applied for all PCR experiments: 5 min at 50°C and 20 s at 95°C, followed by 45 cycles at 95°C for 3 s, and 60°C for 31 s.

Statistical analyses. Statistical analyses were performed using GraphPad Prism 6.0 software (La Jolla, CA, USA). Specific tests are described in the figure legends. P values of ≤0.05 were considered significant. All data were expressed as means ± standard deviations (SDs). Experiments were performed at least in biological triplicates and technical duplicates.

**REFERENCES**

1. Imamura T, Oshitani H. 2015. Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. Rev Med Virol 25:102–114. https://doi.org/10.1002/rmv.1820.

2. Messacar K, Schreiner TL, Maloney JA, Wallace A, Ludke J, Oberste MS, Dominguez SR. 2015. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet 385:1662–1671. https://doi.org/10.1016/S0140-6736(14)62457-0.

3. Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Styrke O, Anderson C, Yagi S, Messenger S, Watford D, Xia D, Watt JP, Van Haren K, Dominguez SR, Glaser C, Aldrovandi PG, Chi DCY. 2015. A novel outbreak enterovirus D68 strain associated with acute flavivirus meningitis in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis 15:671–682. https://doi.org/10.1016/S1473-3099(15)00993-9.

4. Holm-Hansen CC, Midgley SE, Fischer TK. 2016. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis 16:520–535. https://doi.org/10.1016/S1473-3099(15)00543-5.

5. Dyda A, Steiner-Braud S, Adam D, Chughtai AA, MacIntyre CR. 2018. The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68) - what is the evidence for causation? Euro Surveill 23:17-00310. https://doi.org/10.2807/1560-7917.ES.2018.23.3.17-00310.

6. Knoester M, Scholvinck EH, Poelman R, Smit S, Vermont CL, Niesters HG, Johnson D, Giles BL, Patel A, Echols F, Oberste MS, Watson JT, Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Watford D, Xia D, Watt JP, Van Haren K, Dominguez SR, Glaser C, Aldrovandi PG, Chi DCY. 2015. A novel outbreak enterovirus D68 strain associated with acute flavivirus meningitis in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis 15:671–682. https://doi.org/10.1016/S1473-3099(15)00993-9.

7. Furuse Y, Chaimongkol N, Okamoto M, Imamura T, Saito M, Tamaki R, Saito M, Tohoku-RITM Collaborative Research Team, Lupisan SP, Oshitani H. 2015. Molecular epidemiology of enterovirus D68 from 2013 to 2014 in Philippines. J Clin Microbiol 53:1015–1018. https://doi.org/10.1128/JCM.03362-14.

8. Messacar K, Abzug MJ, Dominguez SR. 2016. 2014 outbreak of enterovirus D68 in North America. J Med Virol 88:739–745. https://doi.org/10.1002/jmv.24410.

9. Midgley CM, Jackson MA, Selvarangan R, Turabelidze G, Obringer E, Johnson D, Giles BL, Patel A, Echols F, Oberste MS, Nix WA, Watson JT, Gerber SL. 2014. Severe respiratory illness associated with enterovirus D68 - Missouri and Illinois, 2014. MMWR Morb Mortal Wkly Rep 63: 798–799.

10. Zhang Y, Cao J, Zhang S, Lee AJ, Sun G, Larsen CN, Zhao H, Gu Z, He S, Klem EB, Scheuermann RH. 2016. Genetic changes found in a distinct clade of Enterovirus D68 associated with paralysis during the 2014 outbreak. Virus Evol 2:vew015. https://doi.org/10.1093/viwt/vew015.

11. Yogo N, Imamura T, Muto Y, Hira K. 2019. Cardiopulmonary failure as a result of brainstem encephalitis caused by enterovirus D68. BMJ Case Rep 12:e231990. https://doi.org/10.1136/bcr-2019-231990.

12. Esposito S, Chimenti G, Cinnante C, Napolitano L, Giannini A, Terranova L, Niesters H, Principi N, Calderini E. 2017. Acute flaccid myelitis associated with enterovirus-D68 infection in an otherwise healthy child. Virol J 14:4. https://doi.org/10.1186/s12985-016-0678-0.

13. Kreuter JD, Barnes A, McCarthy JE, Schwartzman JD, Oberste MS, Rhodes CH, Modlin LF, Wright PF. 2011. A fatal central nervous system enterovirus 68 infection. Arch Pathol Lab Med 135:793–796. https://doi.org/10.1043/2010-0174-CR.1.

14. Messacar K, Pretty K, Reno S, Dominguez SR. 2019. Continued biennial circulation of enterovirus D68 in Colorado. J Clin Virol 113:24–26. https://doi.org/10.1016/j.jcv.2019.01.008.

15. Carballo CM, Ero MG, Sordelli N, Vazquez G, Mistchenko AS, Cejas C, Rodriguez M, Cisterna DM, Freire MC, Contrini MM, Lopez EL. 2019. Acute flaccid myelitis associated with enterovirus D68 in children, Argentina, 2016. Emerg Infect Dis 25:573–576. https://doi.org/10.3201/eid2503.170897.

16. Pellegrenilli L, Giardina F, Lunghi G, Ucenda Renteria SC, Greco L, Fratini A, Galli C, Piralla A, Binda S, Pariani E, Baldanti F. 2019. Emergence of divergent enterovirus (EV) D68 sub-clade D1 strains, northern Italy, September to October 2018. Euro Surveill 24:1900090. https://doi.org/10.2807/1560-7917.ES.2018.24.7.1900090.

17. The United Kingdom Acute Flaccid Paralysys AfP Task Force. 2019. An increase in reports of acute flaccid paralysis (AFP) in the United Kingdom, 1 January 2018–21 January 2019: early findings. Euro Surveill 24:1900093. https://doi.org/10.2807/1560-7917.ES.2019.24.6.1900093.

18. Cathcart AL, Baggs EL, Semler BL. 2015. Picornaviruses: pathogenesis and molecular biology. Elsevier Inc, University of California, Irvine, CA, USA.

19. Baggen J, Thibaut HJ, Staring J, Jee LT, Li Y, Guo H, Slinker Jl, de Bruijn JW, van Vliet ALW, Blomen VA, Overduin P, Sheng J, de Haan CAM, de Vries E, Meijer A, Rossmann MG, Bummelkamp TR, van Kuppevelt FJ.M.
2016. Enterovirus D68 receptor requirements unraveled by haploid genetics. Proc Natl Acad Sci U S A 113:1399–1404. https://doi.org/10.1073/pnas.1524948113.

38. Tseliga ED, Sobo K, Stoppini L, Cagno V, Abdul F, Piuz I, Meylan P, Huang S, Chai T, Tapparel C. 2018. A VP1 mutant acquired during an enterovirus 71 dissemination infection confers heparan sulfate binding ability and modulates ex vivo tropism. PLoS Pathog 14:e1007190. https://doi.org/10.1371/journal.ppat.1007190.

39. Jenniskens GJ, Oosterhof A, Brandwijk R, Veerkamp JH, van Kuppevelt TH. 2000. Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. J Neurosci 20: 4099–4111. https://doi.org/10.1523/JNEUROSCI.20-11-04099.2000.

40. Karelehto E, Koen G, Benschop K, van der Klis F, Pajkrt D, Woltkers K. 2019. Enterovirus D68 serosurvey: evidence for endemic circulation in the Netherlands, 2006 to 2016. Euro Surveill 24:1800671. https://doi.org/10.2807/1560-7917.ES.2019.24.18.1800671.

41. Harrison CJ, Weldon WC, Pahud BA, Jackson MA, Oberste MS, Selvaran- gan R. 2019. Neutralizing antibody against enterovirus D68 in children and adults before 2014 outbreak, Kansas City, Missouri, USA. Emerg Infect Dis 25:585–588. https://doi.org/10.1093/ eid/503.180906.

42. Schubert RD, Hawes IA, Ramachandran PS, Ramesh A, Crawford ED, Pak JE, Wu W, Cheung CK, O'Donovan BD, Tato CM, Lyden A, Tan M, Sit R, Sowa GA, Sample HA, Zorn KC, Banerji D, Khan LM, Rauwer HA, Sluier GS, Gelfand AA, Johnson-Kerner BL, Nash K, Krishnamoorthy KS, Chinitis T, Ding JZ, McMillan HJ, Chiu CY, Briggs B, Glaser CA, Yen C, Chu V, Wadfold DA, Dominguez SR, Ng TF, Marine RL, Lopez AS, Nix WA, Slusser A, Gorman MP, Benson KS, Marseglia GL, Baldanti F, Esposito S. 2018. Enterovirus D68 in cerebrospinal fluid of patients with acute flaccid myelitis. Nat Med 24:1748–1752. https://doi.org/10.1038/nm.41467-019-0161-3.

43. Mishra N, Ng TFF, Marine RL, Jain K, Ng J, Thakkar R, Caciuca A, Price A, Garcia JA, Burns JC, Thakur KT, Hetzler RL, Routh JA, Konopka-Anston JL, Nix WA, Tokarz R, Briese T, Oberste MS, Lipkin W. 2019. Antibodies to enteroviruses in cerebrospinal fluid of patients with acute flaccid myelitis. mBio 10:e01903-19. https://doi.org/10.1128/mBio.01903-19.

44. Okumura A, Numoto S, Iwayaama H, Kurasaki H, Natsume J, Saitoh S, Yoshikawa T, Fukuo T, Hirayama M, Takahashi Y. 2020. Respiratory illness and acute flaccid myelitis in the Tokai district in 2018. Pediatr Int 62:337–340. https://doi.org/10.1111/ped.14128.

45. Meijer A, Benschop KS, Donker GA, van der Avoort HG. 2014. Contemporary circulating enterovirus D68 in the Netherlands, 2011–2014. Euro Surveill 19:20935. https://doi.org/10.2807/1560-7917.es.2014.19.42.20935.

46. Meijer A, van der Sanden S, Snijders BE, Jaramillo-Gutierrez G, Bont L, van der Ent CK, Overduin P, Jenny SL, Usice J, van der Avoort HG, Smith GJ, Donker GA, Koopmans MP. 2012. Emergence and epidemic occurrence of enterovirus 68 respiratory infections in The Netherlands in 2010. Virology 423:49–57. https://doi.org/10.1016/j.virology.2011.11.021.

47. Kärber G. 1931. Beitrag zur quantitativen Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 184:97–98. https://doi.org/10.1007/BF01863914.

48. Nikolay B, Weidmann M, Dupressoir A, Faye O, Boye CS, Diallo M, Sall AA. 2016. Acute flaccid myelitis: a clinical review of US cases occurring an outbreak in the United States in 2016. Sci Rep 7:1242. https://doi.org/10.1038/s41598-016-05310-3.

49. Bushnell B. 2018. BBMap download. https://sourceforge.net/projects/bbmap/.

50. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Pyribelski AD, Pyshkin AV, Sirokin AV, Vyshni N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021.

51. Li H. 2018. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34:3309–3410. https://doi.org/10.1093/bioinformatics/bty191.

52. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Kedgley A, Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, Drummond A. 2012. Geneious Basic: an integrated and comprehensive bioinformatics workbench for genome assembly and analysis. Bioinformatics 28:1351–1357. https://doi.org/10.1093/bioinformatics/bts199.

53. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731–2739. https://doi.org/10.1093/molbev/msr121.